SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase

Immunity. 2024 Mar 12;57(3):587-599.e4. doi: 10.1016/j.immuni.2024.01.017. Epub 2024 Feb 22.

Abstract

It is thought that mRNA-based vaccine-induced immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wanes quickly, based mostly on short-term studies. Here, we analyzed the kinetics and durability of the humoral responses to SARS-CoV-2 infection and vaccination using >8,000 longitudinal samples collected over a 3-year period in New York City. Upon primary immunization, participants with pre-existing immunity mounted higher antibody responses faster and achieved higher steady-state antibody titers than naive individuals. Antibody kinetics were characterized by two phases: an initial rapid decay, followed by a stabilization phase with very slow decay. Booster vaccination equalized the differences in antibody concentration between participants with and without hybrid immunity, but the peak antibody titers decreased with each successive antigen exposure. Breakthrough infections increased antibodies to similar titers as an additional vaccine dose in naive individuals. Our study provides strong evidence that SARS-CoV-2 antibody responses are long lasting, with initial waning followed by stabilization.

Keywords: COVID-19 vaccines; SARS-CoV-2 immunity; SARS-CoV-2 variants; antibodies; breakthrough infections; durability; hybrid immunity; longitudinal study; modeling antibody kinetics; reactogenicity.

MeSH terms

  • Antibodies, Viral
  • Antibody Formation
  • COVID-19*
  • Humans
  • Immunization, Secondary
  • SARS-CoV-2
  • Vaccination
  • Vaccines*
  • mRNA Vaccines

Substances

  • Vaccines
  • mRNA Vaccines
  • Antibodies, Viral